Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 20/20 | 1.00 |
| ▸ | CA1 | P00915 | 20/20 | 1.00 |
| ▸ | CA2 | P00918 | 20/20 | 1.00 |
| ▸ | CA6 | P23280 | 20/20 | 1.00 |
| ▸ | CA7 | P43166 | 20/20 | 1.00 |
| ▸ | CA9 | Q16790 | 20/20 | 1.00 |
| ▸ | CA13 | Q8N1Q1 | 20/20 | 1.00 |
| ▸ | CA14 | Q9ULX7 | 20/20 | 1.00 |
| ▸ | CA5B | Q9Y2D0 | 20/20 | 1.00 |
| ▸ | CA5A | P35218 | 19/20 | 1.00 |
| ▸ | CA3 | P07451 | 19/20 | 1.00 |
| ▸ | CA4 | P22748 | 18/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18424372 | 0.88 | CA1 (1.00) | CA12CA1CA2CA6CA7 | |
| SCHEMBL18426074 | 0.88 | CA12 (1.00) | CA12CA1CA2CA6CA7 | |
| SCHEMBL18423868 | 0.85 | CA12 (1.00) | CA12CA1CA2CA6CA7 | |
| SCHEMBL18425938 | 0.84 | CA1 (1.00) | CA12CA1CA2CA6CA7 | |
| SCHEMBL31670552 | 0.83 | CA12 (0.71) | CA12CA1CA2CA6CA7 | |
| SCHEMBL18425872 | 0.82 | CA12 (1.00) | CA12CA1CA2CA6CA7 | |
| SCHEMBL31670543 | 0.82 | CA12 (1.00) | CA12CA1CA2CA6CA7 | |
| SCHEMBL18425356 | 0.81 | CA12 (1.00) | CA12CA1CA2CA6CA7 | |
| SCHEMBL18423559 | 0.81 | CA1 (0.68) | CA12CA1CA2CA6CA7 | |
| SCHEMBL18425351 | 0.81 | CA12 (1.00) | CA12CA1CA2CA6CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3328833-B1 | SELECTIVE INHIBITORS OF CARBONIC ANHYDRASE | UNIV VILNIUS (LT) | 2025-08-06 | — | — | EP | claimed |
| US-11312682-B2 | Selective inhibitors of carbonic anhydrase | VILNIUS UNIVERSITY (LT) | 2022-04-26 | — | — | US | claimed |
| US-20180222856-A1 | SELECTIVE INHIBITORS OF CARBONIC ANHYDRASE | VILNIUS UNIVERSITY (LT) | 2018-08-09 | — | — | US | claimed |
| EP-3328833-A1 | SELECTIVE INHIBITORS OF CARBONIC ANHYDRASE | Vilnius University (LT) | 2018-06-06 | — | — | EP | claimed |
| WO-2017017505-A1 | SELECTIVE INHIBITORS OF CARBONIC ANHYDRASE | VILNIUS UNIVERSITY (LT) | 2017-02-02 | — | — | WO | claimed |
| EP-3328833-B1 | SELECTIVE INHIBITORS OF CARBONIC ANHYDRASE | UNIV VILNIUS (LT) | 2025-08-06 | — | — | EP | disclosed |
| US-11312682-B2 | Selective inhibitors of carbonic anhydrase | VILNIUS UNIVERSITY (LT) | 2022-04-26 | — | — | US | disclosed |
| US-20180222856-A1 | SELECTIVE INHIBITORS OF CARBONIC ANHYDRASE | VILNIUS UNIVERSITY (LT) | 2018-08-09 | — | — | US | disclosed |
| EP-3328833-A1 | SELECTIVE INHIBITORS OF CARBONIC ANHYDRASE | Vilnius University (LT) | 2018-06-06 | — | — | EP | disclosed |
| WO-2017017505-A1 | SELECTIVE INHIBITORS OF CARBONIC ANHYDRASE | VILNIUS UNIVERSITY (LT) | 2017-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11312682-B2 | Selective inhibitors of carbonic anhydrase | CA2, CA9, CA7 | CA12 8/4885CA1 6/4885CA2 1/4885 |
| US-20180222856-A1 | SELECTIVE INHIBITORS OF CARBONIC ANHYDRASE | CA9, CA2, CA7 | CA12 8/4885CA1 6/4885CA2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.